Fortress Biotech, Inc. (NASDAQ:FBIO - Get Free Report) CEO Lindsay Md Rosenwald acquired 64,491 shares of the firm's stock in a transaction on Tuesday, November 17th. The shares were acquired at an average price of $1.80 per share, with a total value of $116,083.80. Following the completion of the purchase, the chief executive officer owned 4,651,332 shares of the company's stock, valued at $8,372,397.60. This trade represents a 1.41% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Fortress Biotech Stock Down 5.7%
FBIO stock traded down $0.11 during mid-day trading on Thursday, hitting $1.78. 194,841 shares of the company were exchanged, compared to its average volume of 586,980. The firm has a fifty day simple moving average of $2.08 and a 200 day simple moving average of $2.70. Fortress Biotech, Inc. has a twelve month low of $1.64 and a twelve month high of $4.53. The company has a market capitalization of $60.16 million, a PE ratio of 0.78 and a beta of 1.27. The company has a current ratio of 2.93, a quick ratio of 3.83 and a debt-to-equity ratio of 0.10.
Fortress Biotech (NASDAQ:FBIO - Get Free Report) last released its quarterly earnings data on Friday, November 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.04. Fortress Biotech had a net margin of 143.04% and a return on equity of 61.84%. The firm had revenue of $19.16 million for the quarter, compared to analyst estimates of $21.57 million.
Analysts Set New Price Targets
A number of research firms recently issued reports on FBIO. Wall Street Zen lowered Fortress Biotech from a "strong-buy" rating to a "hold" rating in a report on Saturday, August 15th. Weiss Ratings lowered Fortress Biotech from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, October 23rd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $17.00.
Read Our Latest Report on FBIO
Hedge Funds Weigh In On Fortress Biotech
A number of hedge funds have recently made changes to their positions in FBIO. Marshall Wace LLP bought a new position in shares of Fortress Biotech during the third quarter valued at $462,000. Renaissance Technologies LLC lifted its holdings in Fortress Biotech by 22.8% during the 1st quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company's stock valued at $278,000 after purchasing an additional 18,490 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Fortress Biotech in the second quarter valued at about $47,000. Institutional investors and hedge funds own 96.51% of the company's stock.
Recent Fortress Biotech Headlines
Here are a few of the latest headlines about FBIO:
- Positive Sentiment: CEO Lindsay Rosenwald bought 136,723 shares across three transactions from November 17–19, spending about $253,000. CFO David Jin also bought 47,605 shares over the same period for approximately $88,000. These open-market purchases increased both executives’ holdings and may signal confidence in the company. CEO SEC filing CFO SEC filing
- Neutral Sentiment: HC Wainwright forecast EPS of $2.66 for FY2026 and $2.37 for FY2027. The report also estimated a Q4 2026 loss of $0.15 per share; the articles did not provide a rating change or explain the basis for the annual forecasts. Analyst insights article
About Fortress Biotech
(
Get Free Report)
Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company's activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fortress Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortress Biotech wasn't on the list.
While Fortress Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.